Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned

Aditxt, Inc.

Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.
CEO Amro Albanna stated 70% of cancer deaths could be prevented if caught early; Pearsanta aims for early detection via non-invasive blood test.
Aditxt plans to spin off Pearsanta via IPO, retaining ~60% ownership; values Aditxt's stake potentially at $60M vs. current $5M market cap.
The test will initially run at CLIA/CAP lab in Richmond, VA; FDA submission for kit development planned later.
Other subsidiaries highlighted: Adimune (autoimmunity) and pending Adifem/Evofem acquisition (women's health) expected to close by September 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.